-- Orthocell（ASX：OCC）周二向澳大利亚证券交易所提交的文件显示，其神经修复产品Remplir正在进行的多中心上市后临床随访研究结果显示，基于66名患者的疗效数据，总体治疗成功率接近90%。 该公司表示，超过90%的运动神经修复手术实现了肌肉功能恢复，而超过89%的神经减压手术实现了症状的完全缓解或显著改善。 患者年龄在14岁至82岁之间，大多数手术在上肢进行。未报告任何术后并发症或不良反应。 Orthocell的股价在周二的交易中上涨了近4%。
Related Articles
Asia
Raytron Tech's Q1 Profit Surges 228%, Revenue Jumps 71%; Shares Up 5%
Raytron Technology's (SHA:688002) net profit attributable to shareholders in the first quarter surged 228% to 478.7 million yuan from 145.8 million yuan a year earlier, according to a Shanghai bourse filing on Tuesday.Earnings per share soared 211% year on year to 0.98 yuan from 0.32 yuan.Operating revenue jumped 71% to 1.94 billion yuan from 1.14 billion yuan in the prior year.Raytron manufactures uncooled infrared thermal imaging products. Its shares jumped 5% during the afternoon trade.
$SHA:688002
Asia
Jefferies Adjusts Perfect World's Price Target to 19.80 Yuan from 20.60 Yuan, Keeps at Buy
$SHE:002624
Asia
BP Plastics Strikes Off Dormant Unit; Shares Drop 3%
BP Plastics (KLSE:BPPLAS) unit BPPLAS Plantation has been struck off and deemed dissolved from the Companies Commission of Malaysia, according to a Monday Malaysian bourse filing.Shares fell about 3% in Tuesday's midday trade.BPPLAS Plantation was dormant with no future business plans, was dissolved as part of a cost and administrative streamlining exercise.The group said the dissolution will not have a material impact on earnings or net assets.
$KLSE:BPPLAS